Maze Therapeutics, Inc. (NASDAQ:MAZE) Given Average Recommendation of “Buy” by Analysts

Shares of Maze Therapeutics, Inc. (NASDAQ:MAZE) have earned an average recommendation of “Buy” from the eleven research firms that are covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, eight have given a buy recommendation and two have given a strong buy recommendation to the company. The average twelve-month price objective among brokerages that have covered the stock in the last year is $66.00.

A number of research analysts have recently weighed in on MAZE shares. Truist Financial reduced their target price on shares of Maze Therapeutics from $68.00 to $64.00 and set a “buy” rating for the company in a research report on Tuesday, April 14th. Wall Street Zen raised shares of Maze Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, May 16th. Guggenheim increased their target price on shares of Maze Therapeutics from $46.00 to $58.00 and gave the company a “buy” rating in a research report on Wednesday, March 4th. Mizuho raised shares of Maze Therapeutics to a “strong-buy” rating in a research report on Wednesday, March 11th. Finally, JPMorgan Chase & Co. raised their price objective on shares of Maze Therapeutics from $52.00 to $58.00 and gave the stock an “overweight” rating in a report on Tuesday, March 31st.

Insider Buying and Selling at Maze Therapeutics

In related news, insider Atul Dandekar sold 7,500 shares of the firm’s stock in a transaction that occurred on Wednesday, April 29th. The shares were sold at an average price of $25.37, for a total value of $190,275.00. Following the completion of the transaction, the insider directly owned 10,503 shares of the company’s stock, valued at approximately $266,461.11. This trade represents a 41.66% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Amy Bachrodt sold 2,500 shares of the firm’s stock in a transaction that occurred on Wednesday, April 1st. The stock was sold at an average price of $29.44, for a total transaction of $73,600.00. Following the completion of the transaction, the senior vice president directly owned 12,965 shares of the company’s stock, valued at approximately $381,689.60. This trade represents a 16.17% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 119,502 shares of company stock valued at $4,246,639 in the last quarter. Corporate insiders own 5.30% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of MAZE. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new stake in Maze Therapeutics in the 1st quarter worth approximately $57,000. Goldman Sachs Group Inc. purchased a new stake in Maze Therapeutics in the 1st quarter worth approximately $145,000. Rhumbline Advisers purchased a new stake in Maze Therapeutics in the 1st quarter worth approximately $80,000. Geode Capital Management LLC lifted its stake in Maze Therapeutics by 8.8% in the 2nd quarter. Geode Capital Management LLC now owns 231,237 shares of the company’s stock worth $2,838,000 after purchasing an additional 18,773 shares in the last quarter. Finally, Legal & General Group Plc lifted its stake in Maze Therapeutics by 387.0% in the 2nd quarter. Legal & General Group Plc now owns 4,242 shares of the company’s stock worth $52,000 after purchasing an additional 3,371 shares in the last quarter.

Maze Therapeutics Stock Down 4.6%

Maze Therapeutics stock opened at $24.29 on Friday. Maze Therapeutics has a twelve month low of $9.83 and a twelve month high of $53.65. The firm has a 50 day moving average price of $28.29 and a 200-day moving average price of $37.52. The company has a market capitalization of $1.34 billion, a P/E ratio of -9.60 and a beta of 2.26. The company has a quick ratio of 17.88, a current ratio of 17.88 and a debt-to-equity ratio of 0.11.

Maze Therapeutics (NASDAQ:MAZE) last released its earnings results on Tuesday, May 12th. The company reported ($0.45) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.02). The firm had revenue of $20.00 million for the quarter. As a group, equities analysts predict that Maze Therapeutics will post -2.74 EPS for the current year.

Maze Therapeutics Company Profile

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical?stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de?risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.